Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transdel Pharmaceuticals, a developer of non-invasive, topically-delivered medications, has announced plans to expand its product development programs to include cosmetic or cosmeceutical products, which will utilize the company's patented transdermal delivery system technology, Transdel.
Subscribe to our email newsletter
Besides its lead drug, Ketotransdel (a topical nonsteroidal antiinflammatory drug currently in a Phase III trial for acute pain), the company is exploring potential co-development opportunities with corporate partners to expand its program into other therapeutic areas.
The company’s patent for its Transdel technology specifically lists over 500 different drugs in over 60 therapeutic areas, including both approved and established drugs. The Transdel technology may also have an application to deliver drugs not listed in its patent, including novel drugs, and the company is seeking partnerships in this area as well.
The company has initiated discussions with potential sales and marketing partners for specific cosmetic or cosmeceutical products.
Juliet Singh, president and CEO of Transdel Pharmaceuticals, said: “The expansion into the cosmetic or cosmeceutical market may allow the company to generate revenue during 2009.”